Page 3 - Cancer Drugs

Sun Pharma, Britain's AstraZeneca join to distribute cancer drugs in China

The financial terms of the agreement, which has an initial tenure of 10 years, were not disclosed

Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge

Excluding special items, Pfizer earned 75 cents per share, topping analysts' average estimate by 13 cents

Ranitidine cancer threat: Expect more clarity on products in coming weeks

Ranitidine sales account for 2 per cent of Strides sales and 6 per cent of its profit after tax

Bills for pills: Antibiotics could be govt's next segment for price cap

Centre likely to consider rationalising trade margins

Why aren't cancer drugs better? The targets might be wrong

Drugs can stop cancer cells if they attack the right proteins. But a new study suggests many of these targets were chosen with dated, imprecise technology, writes Carl Zimmer

Telangana businessman claims credit for cap on retail price of cancer drugs

Tractor dealer Purushottam Somani contacted PMO after finding difference of up to 1,000 per cent between wholesale price and MRP, says diabetes and other drugs next on radar